These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 29778265)

  • 1. A Guide to the Economics of Hepatitis C Virus Cure in 2017.
    Linas BP; Nolen S
    Infect Dis Clin North Am; 2018 Jun; 32(2):447-459. PubMed ID: 29778265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Localized US Efforts to Eliminate Hepatitis C.
    Gaudino A; Gay B; Garmon C; Selick M; Vreeland R; Burk K; Huriaux E; Facente SN; Luetkemeyer A; Waters P; Graham CS
    Infect Dis Clin North Am; 2018 Jun; 32(2):293-311. PubMed ID: 29778257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C eradication: A long way to go.
    Waheed Y
    World J Gastroenterol; 2015 Nov; 21(43):12510-2. PubMed ID: 26604658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Road to Hepatitis C Virus Cure: Practical Considerations from a Health System's Perspective.
    Jonas MC; Loftus B; Horberg MA
    Infect Dis Clin North Am; 2018 Jun; 32(2):481-493. PubMed ID: 29778267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathways to the elimination of hepatitis C: prioritising access for all.
    Pedrana AE; Sacks-Davis R; Doyle JS; Hellard ME
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1023-1026. PubMed ID: 28942660
    [No Abstract]   [Full Text] [Related]  

  • 7. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma.
    Gentile I; Maraolo AE; Niola M; Graziano V; Borgia G; Paternoster M
    Expert Rev Gastroenterol Hepatol; 2016 Nov; 10(11):1227-1234. PubMed ID: 27607920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five Questions Concerning Managing Hepatitis C in the Justice System: Finding Practical Solutions for Hepatitis C Virus Elimination.
    Spaulding AC; Adee MG; Lawrence RT; Chhatwal J; von Oehsen W
    Infect Dis Clin North Am; 2018 Jun; 32(2):323-345. PubMed ID: 29778259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hepatitis C: cost of eradication ].
    Nau JY
    Rev Med Suisse; 2014 Jan; 10(415):306-7. PubMed ID: 24624702
    [No Abstract]   [Full Text] [Related]  

  • 10. The economics of hepatitis C virus.
    Shah BB; Wong JB
    Clin Liver Dis; 2006 Nov; 10(4):717-34. PubMed ID: 17164114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The case for a universal hepatitis C vaccine to achieve hepatitis C elimination.
    Scott N; Wilson DP; Thompson AJ; Barnes E; El-Sayed M; Benzaken AS; Drummer HE; Hellard ME
    BMC Med; 2019 Sep; 17(1):175. PubMed ID: 31530275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling.
    Chhatwal J; Chen Q; Aggarwal R
    Infect Dis Clin North Am; 2018 Jun; 32(2):461-480. PubMed ID: 29778266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HEPCARE EUROPE- A case study of a service innovation project aiming at improving the elimination of HCV in vulnerable populations in four European cities.
    Avramovic G; Reilly M; Cullen W; Macías J; McCombe G; McHugh T; Oprea C; Story A; Surey J; Sabin C; Bivegete S; Vickerman P; Walker J; Ward Z; Lambert JS
    Int J Infect Dis; 2020 Dec; 101():374-379. PubMed ID: 32992012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elimination of Hepatitis C Virus in Australia: Laying the Foundation.
    Dore GJ; Hajarizadeh B
    Infect Dis Clin North Am; 2018 Jun; 32(2):269-279. PubMed ID: 29778255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs.
    Martinello M; Dore GJ; Matthews GV; Grebely J
    Infect Dis Clin North Am; 2018 Jun; 32(2):371-393. PubMed ID: 29778261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
    Goel A; Chen Q; Chhatwal J; Aggarwal R
    J Gastroenterol Hepatol; 2018 Dec; 33(12):2029-2036. PubMed ID: 29864213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort.
    Maier MM; Zhou XH; Chapko M; Leipertz SL; Wang X; Beste LA
    Dig Dis Sci; 2018 Jun; 63(6):1454-1462. PubMed ID: 29453610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A path to eradication of hepatitis C in low- and middle-income countries.
    Graham CS; Swan T
    Antiviral Res; 2015 Jul; 119():89-96. PubMed ID: 25615583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can hepatitis C virus be eliminated by 2030? Saudi Arabia as an example.
    Altraif I
    Saudi Med J; 2018 Aug; 39(8):842-845. PubMed ID: 30106425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can hepatitis C be eradicated in the United States?
    Edlin BR; Winkelstein ER
    Antiviral Res; 2014 Oct; 110():79-93. PubMed ID: 25110202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.